5/7/2023 0 Comments Home designer suite 2015 trialFindingsīetween May 15, 2009, and July 8, 2014, we screened 436 patients, of whom 335 were randomly assigned. The trial is registered with EudraCT number 2008-007149-30, and number, NCT02369081. The hierarchical primary endpoints were the difference in averaged home systolic blood pressure between spironolactone and placebo, followed (if significant) by the difference in home systolic blood pressure between spironolactone and the average of the other two active drugs, followed by the difference in home systolic blood pressure between spironolactone and each of the other two drugs. The dose was doubled after 6 weeks of each cycle. Investigators and patients were masked to the identity of drugs, and to their sequence allocation. Random assignment was done via a central computer system. Patients rotated, in a preassigned, randomised order, through 12 weeks of once daily treatment with each of spironolactone (25–50 mg), bisoprolol (5–10 mg), doxazosin modified release (4–8 mg), and placebo, in addition to their baseline blood pressure drugs. In this double-blind, placebo-controlled, crossover trial, we enrolled patients aged 18–79 years with seated clinic systolic blood pressure 140 mm Hg or greater (or ≥135 mm Hg for patients with diabetes) and home systolic blood pressure (18 readings over 4 days) 130 mm Hg or greater, despite treatment for at least 3 months with maximally tolerated doses of three drugs, from 12 secondary and two primary care sites in the UK. The Lancet Regional Health – Western Pacific.The Lancet Regional Health – Southeast Asia. The Lancet Gastroenterology & Hepatology.
0 Comments
Leave a Reply. |